차백신연구소
Financials
Valuation Metrics
차백신연구소's Market Cap is ₩578B. At end of 2025 it was ₩791B. Ranked #1635 of 2,436 in KR market (top 67%), #970 of 1,649 on KOSDAQ (top 59%), #181 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 77%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 57.85B KRW | KR#1,635/2,436 Sec#181/234 |
| Revenue | 158.6M KRW | KR#2,399/2,436 Sec#226/234 |
| Net Income | -15.54B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 21.99B KRW | KR#2,363/2,436 Sec#228/234 |
| Net Assets | 9.59B KRW | KR#2,369/2,436 Sec#227/234 |
| Employees | 56 | KR#1,982/2,436 Sec#176/234 |
| Value | ||
| P/B | 6.03x | KR#2,272/2,436 Sec#190/234 |
| P/S | 364.71x | KR#2,406/2,436 Sec#222/234 |
| FCF Yield | -19.25% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -162.06% | KR#2,366/2,436 Sec#224/234 |
| ROA | -70.68% | KR#2,371/2,436 Sec#224/234 |
| Op. Margin | -8558.60% | KR#2,400/2,436 Sec#226/234 |
| Revenue Growth | -57.21% | KR#2,301/2,436 Sec#203/234 |
| Financial Health | ||
| Debt Ratio | 229.26% | KR#1,895/2,436 Sec#206/234 |
| Total Debt | 5.92B KRW | KR#1,754/2,436 Sec#167/234 |
| FCF | -11.13B KRW | KR#1,745/2,436 Sec#154/234 |
| Cash | 2.23B KRW | KR#2,223/2,436 Sec#212/234 |
| Current Ratio | 1.82x | KR#1,066/2,436 Sec#118/234 |
| Performance | ||
| 1Y Return | -26.77% | KR#1,483/2,436 Sec#129/234 |
| 1M Return | -21.48% | KR#2,236/2,436 Sec#221/234 |
| From 52W High | -69.27% | KR#2,106/2,436 Sec#188/234 |
| 1Y MDD | -67.42% | KR#1,816/2,436 Sec#152/234 |
| Trading | ||
| Volume | 267,967 shares | KR#443/2,436 Sec#43/234 |
| Foreign Own. | 0.00% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -579 KRW | KR—/2,436 Sec—/234 |
| BPS | 357 KRW | KR#2,415/2,436 Sec#231/234 |
Company Info
CHA Vaccine Institute, a bio venture company established in 2000, joined the CHA Hospital/CHA Bio Group in 2011 when CHA Biotech became its largest shareholder. Utilizing its independently developed immune-enhancing platform technology, the company is developing next-generation vaccines, including therapeutic vaccines for chronic Hepatitis B, and anti-cancer immunotherapeutics. Its immune enhancers boost immune responses to vaccine antigens; specifically, Lipo-pam® is ideal for therapeutic vaccine development due to its ability to induce strong cellular immune responses. CHA Vaccine Institute is headquartered in Seongnam-si, Gyeonggi-do.